Royalty Pharma (RPRX) Revenue (2019 - 2026)
Royalty Pharma (RPRX) posted Revenue of $630.6 million for Q1 2026, up 1.38% sequentially from $622.0 million in Q4 2025, and up 10.97% YoY from $568.2 million in Q1 2025.
Royalty Pharma (RPRX) Revenue (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Revenue for 8 years, with the latest figure at $630.6 million in Q1 2026.
- Quarterly Revenue rose 10.97% year-over-year to $630.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 7.8% YoY) and the FY2025 annual result came in at $2.4 billion, up 5.06% from the prior year.
- Revenue rose to $630.6 million in Q1 2026 per RPRX's latest filing, from $622.0 million in the prior quarter.
- Over five years, Revenue peaked at $684.0 million in Q1 2023 and troughed at $536.0 million in Q2 2022.
- A 5-year average of $580.2 million and a median of $568.2 million in 2025 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2024: Revenue rose 21.69% in 2023, then fell 16.96% in 2024.
- Over 5 years, Revenue stood at $565.7 million in 2022, then gained by 5.36% to $596.1 million in 2023, then retreated by 0.41% to $593.6 million in 2024, then increased by 4.78% to $622.0 million in 2025, then rose by 1.38% to $630.6 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $630.6 million, $622.0 million, and $609.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 674.14 Mn |
| Mar 31, 2026 | 630.58 Mn |
| Dec 31, 2025 | 621.99 Mn |
| Sep 30, 2025 | 609.29 Mn |
| Jun 30, 2025 | 578.67 Mn |
| Mar 31, 2025 | 568.25 Mn |
| Dec 31, 2024 | 593.64 Mn |
| Sep 30, 2024 | 564.69 Mn |
| Jun 30, 2024 | 537.27 Mn |
| Mar 31, 2024 | 567.98 Mn |
| Dec 31, 2023 | 596.07 Mn |
| Sep 30, 2023 | 536.31 Mn |
| Jun 30, 2023 | 538.20 Mn |
| Mar 31, 2023 | 683.97 Mn |
| Dec 31, 2022 | 565.75 Mn |
| Sep 30, 2022 | 573.46 Mn |
| Jun 30, 2022 | 535.96 Mn |
| Mar 31, 2022 | 562.05 Mn |
| Dec 31, 2021 | 575.70 Mn |
| Sep 30, 2021 | 585.77 Mn |